Sgmo stock price touched intra-day lows at $0

sgmo stock price touched intra-day lows at $0.52 yesterday after reports of competitive therapies entering late-stage trials. This raised concerns about market share retention for Sangamo's lead candidates. As such, the Zacks rating upgrade for Sangamo is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. Sangamo’s another key pipeline candidate is isaralgagene civaparvovec, or ST-920, an investigational gene therapy for the treatment of Fabry disease. The company plans to seek accelerated approval for isaralgagene civaparvovec from the FDA based on data from the ongoing phase I/II STAAR study. It expects to file a biologics license application to the FDA in the second half of 2025. Traders tracking sgmo stock price point to a symmetrical triangle forming on the daily chart, a common precursor to breakout moves in high-beta biotech stocks.